Literature DB >> 1909749

Anti-anginal therapy and quality of life. A comparison of the effects of transdermal nitroglycerin and long-acting oral nitrates.

A Nissinen1, I Wiklund, T Lahti, J Akkila, A Wilson, M Wahl, P Puska.   

Abstract

A total of 112 male patients with severe effort-induced angina pectoris (New York Heart Association functional classes II and III) participated in a randomized open trial consisting of a 6 month phase with 3 month treatment cross-overs. The aim of the study was to compare the effect of transdermal nitroglycerin (TN) patches and long-acting oral nitrates (LAON) on quality of life (QL). During the cross-over period 30 patients (20 on TN and 10 on LAON) withdrew from the study, over half of them within the first month. Although the results should be interpreted with some caution, they showed that improvement in QL was present for both treatments but greater during the transdermal therapy (unadjusted p = 0.07, adjusted p = 0.03). Anginal attacks were associated with improved QL scores, and fewer attacks occurred on TN (p = 0.06). Improvement in QL was most pronounced in patients whose recorded duration of angina was less than 8 years.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1909749     DOI: 10.1016/0895-4356(91)90070-p

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  6 in total

Review 1.  Intermittent or continuous transdermal nitroglycerin: still an issue, or is the case closed?

Authors:  T O Klemsdal; K Gjesdal
Journal:  Cardiovasc Drugs Ther       Date:  1996-03       Impact factor: 3.727

2.  Translating safety, efficacy and compliance into economic value for controlled release dosage forms.

Authors:  M P Cramer; S R Saks
Journal:  Pharmacoeconomics       Date:  1994-06       Impact factor: 4.981

Review 3.  Review of quality-of-life evaluations in patients with angina pectoris.

Authors:  A Gandjour; K W Lauterbach
Journal:  Pharmacoeconomics       Date:  1999-08       Impact factor: 4.981

Review 4.  Review of available instruments and methods for assessing quality of life in anti-anginal trials.

Authors:  B D Bliven; C P Green; J A Spertus
Journal:  Drugs Aging       Date:  1998-10       Impact factor: 3.923

5.  Psychometric properties of a specific quality of life questionnaire in angina pectoris patients.

Authors:  P Marquis; C Fayol; J E Joire; A Leplège
Journal:  Qual Life Res       Date:  1995-12       Impact factor: 4.147

6.  Quality of Life Assessment in Trials of Revascularization for Chronic Stable Angina: Insights from ORBITA and the Implications of Blinding.

Authors:  Alexandra N Nowbar; Darrel P Francis; Rasha K Al-Lamee
Journal:  Cardiovasc Drugs Ther       Date:  2021-08-21       Impact factor: 3.947

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.